In addition, CD47ASO treatment reduced hepatic steatosis as demonstrated by reduced liver Oil Red O staining and liver triglyceride measurement (Fig. 3A,B), which was associated with reduced expression of lipid synthesis genes including FAS, ACC and SCD1 (Fig. 3C). This evidence concerns the gene FAS and Hepatic steatosis.